Anshul Saigal analyzes the potential returns of PSBs compared to private banks, discusses VIP and Safari s competition, and highlights the impact of US FDA regulations on Indian pharma companies, emphasizing improving business models. On Piramal Pharma and Wockhardt, he points out their business models are improving without recommending a buy.
Wockhardt has two molecules Nafithromycin (WCK 4873) for treating pneumonia and WCK 5222 for urinary tract infection, in development phases, with launched lined up for FY25 and FY26
Wockhardt plans to clear debt, fund antibiotic trials with QIP funds. Khorakiwala expects revenue growth, EBITDA rise, and completion of global antibiotic trial for innovations like WCK5222 and WCK4873.
The equity market was trading higher on Wednesday. Sensex rose 551 points to 73,021 and Nifty gained 169 pts to 22,173. Here s a look at hot stocks likely to remain in action today.